New Interactive FDA Device Review Is Significant, But Goes Only So Far
This article was originally published in The Gray Sheet
Executive Summary
An FDA staffer trying to create an informal, "interactive review" process for devices warned companies last week that even under the new system they should not expect extensive discussion without temporarily halting review of an application
You may also be interested in...
Interactive Review May Be Revamped In 2012 User Fee Agreement
Acknowledging the shortcomings of the program, FDA is considering improving the interactive review process as part of its negotiations with industry on reauthorizing the medical device user fee program.
Interactive Review May Be Revamped In 2012 User Fee Agreement
Acknowledging the shortcomings of the program, FDA is considering improving the interactive review process as part of its negotiations with industry on reauthorizing the medical device user fee program.
FDA Gets “Interactive” In New Premarket Guidance Document
A Dec. 28 final FDA guidance document lays out a path for more informal interaction between agency reviewers and device companies while preserving CDRH's options to place holds on premarket reviews